Enterprise Value

74.52M

Cash

113.3M

Avg Qtr Burn

-28.5M

Short % of Float

12.43%

Insider Ownership

1.00%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Ganaxolone (ZTALMY) Details
Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder

Approved

Quarterly sales

Ganaxolone Details
Tuberous sclerosis complex

Phase 3

Data readout

Ganaxolone Details
Epilepsy, Refractory Status Epilepticus

Phase 3

Update

Phase 2

Initiation

Ganaxolone Details
Established Status Epilepticus

Failed

Discontinued